Pharmacophore an International Research Journal
Pharmacophore
Submit Manuscript
Open Access | Published: 2020 - Issue 6

An Overview of Hemophilia Diagnosis and Management in Children Download PDF


Bayan R. Samman, Eman T. Alrumaih, Alsulaiman Lojain Abdullah A, Mishal M. Alrsheedi, Maha D. Aldhafeeri, Afnan A. Alasiry, Khalid S. Alharbi, Bashayr S. Alosaimi, Noura H. Alotaibi, Raed A. Mohammed
Abstract

Background: The most common severe hereditary hemorrhagic disorder is Hemophilia. Philia means Love and Hemo means blood. A and B hemophilia are the two types of hemophilia that result from factor VIII and factor IX protein deficiency, respectively. After minor trauma or sometimes even spontaneously, the features of hemophilia are prolonged and excessive bleeding. Due to deficiency of clotting factor XI, the third rare type C occurs and is common in Ashkenazi Jews. Sometimes, acquired hemophilia can be associated with age or childbirth, which usually resolves with appropriate treatment. Hemophilia A is the most common between them. It presents in 1 out of every 5,000 newborn children worldwide. Objectives: We aimed to review the literature reviewing the types of hemophilia in children, along with the etiology, clinical features, evaluation, diagnosis, and management of these types. Methodology: PubMed database was used for articles selection, papers were obtained and reviewed. Conclusion: Hemophilia is an inherited disorder of coagulation. This condition may lead to severe restrictions in everyday activity and severe complications. Proper recognition, testing, and management of individuals afflicted by this condition will greatly improve the chances of survival, improved quality of life, and reduce the risk of complications. Emerging therapies, such as gene therapy, may provide the possibility of a cure.

Cite this article

QR code:

Short Link:
Quick Access

Pharmacophore
ISSN: 2229-5402

Pharmacophore
© 2024 All rights reserved
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.